Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1/2 1Phase 1 1

Status

Recruiting 4Not yet recruiting 1

Sponsor Class

OTHER 5INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 8Gynecologic 5Thoracic 3CNS 3Other solid neoplasm 2Dermatologic 2Head & Neck 1

Conditions

Uterine Cervical Neoplasms 1Phase IB 1Ovarian Neoplasms 1Neoplasms 1Mesonephric Gynecologic Cancer 1Low-Grade Serous Ovarian Cancer 1

Interventions

Paclitaxel 268Carboplatin 264Cisplatin 194Bevacizumab 135pembrolizumab 99Surveys and Questionnaires 84Radiotherapy 77Cyclophosphamide 75olaparib 67Blood Specimen Collection 65Drug Therapy 62Hyperthermic Intraperitoneal Chemotherapy 60Gemcitabine 60niraparib 56Topotecan 56Brachytherapy 54liposomal doxorubicin 52Taxes 47Docetaxel 46Magnetic Resonance Spectroscopy 43Letrozole 36Cytoreduction Surgical Procedures 36Filgrastim 33Biopsy 33Surgical Procedures, Operative 32durvalumab 31Specimen Handling 31Doxorubicin 31Nivolumab 30Albumin-Bound Paclitaxel 28

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
OTHER × defactinib × Gynecologic × Clear all
NCT05787561 2026-04-28

A Study of Avutometinib (VS-6766) and Defactinib in People With Mesonephric Gynecologic Cancer

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
40 enrolled
Gynecologic

Mesonephric Gynecologic Cancer

NCT06394804 2026-04-23

CHAMELEON

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
20 enrolled
Gynecologic

Low-Grade Serous Ovarian Cancer

NCT07318324 2026-01-06

Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer

M.D. Anderson Cancer Center

Phase 1 Not yet recruiting
31 enrolled
Gynecologic

Phase IB

NCT05512208 2025-10-22

DURAFAK

University of Oklahoma

Phase 2 Recruiting
55 enrolled
Gynecologic

Uterine Cervical Neoplasms

NCT03287271 2024-08-12

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California, San Diego

Phase 1/2 Recruiting
90 enrolled
Gynecologic

Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡